COL18A1 and non-small cell lung carcinoma: A retrospective clinical study has demonstrated that the combination of ICIs with endostatin offers greater efficacy and safety than the combination of ICIs with chemotherapy in treating advanced non-small cell lung cancer (NSCLC) (11).